# Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> clinical trial · VERIFIED · 2026-07-16

Status: RECRUITING · Sponsor: M.D. Anderson Cancer Center · Condition: Recurrent Chronic Lymphocytic Leukemia

- Company: M.D. Anderson Cancer Center
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT04169737

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.